We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+71.58%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$42.1M
Cap. Flow
-$52.8M
Cap. Flow %
-14.65%
Top 10 Hldgs %
79.82%
Holding
22
New
1
Increased
–
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$5.82M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$22.9M
2
ERAS icon
Erasca
ERAS
+$22.7M
3
ELVN icon
Enliven Therapeutics
ELVN
+$11.9M
4
RLYB icon
Rallybio
RLYB
+$1.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q1 2026 Portfolio in Review

As of Q1 2026, 5AM Venture Management held 22 positions worth $360M, up 13% from $318M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

5AM Venture Management withdrew a net $52.8M in Q1 2026, closing 2 positions and reducing 2 holdings. Its most notable exit was Viridian Therapeutics, an estimated $22.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, 5AM Venture Management opened a new position in ALX Oncology worth $6.13M.

  • 5AM Venture Management's largest Q1 2026 buy was ALX Oncology: 3,057,325 shares worth $6.13M.
  • 5AM Venture Management's biggest Q1 2026 reduction was Erasca, cutting an estimated $22.7M.
  • 5AM Venture Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $22.9M.
  • 5AM Venture Management's ten largest holdings make up 80% of its $360M portfolio in Q1 2026.
  • 5AM Venture Management opened 1 new position and closed 2 in Q1 2026.
  • 5AM Venture Management's portfolio value rose 13% quarter-over-quarter to $360M.

Based on 5AM Venture Management's 13F filing for Q1 2026, filed 15 May 2026.